Peritoneal (Abdominal Mesothelioma)
Analysis of Ki67 Protein Expression and Clinicopathological Features in Patients with Peritoneal Mesothelioma
Alternative Therapies in Health and Medicine 2023 December 8 [Link] Dujuan Yang, Yeping Zhou, Kongdan Lv Abstract Background: At present, there are many treatments for peritoneal mesothelioma, but the treatment of peritoneal mesothelioma is still facing great challenges. Distant metastasis is the main cause of poor prognosis and death of patients with peritoneal mesothelioma. Ki67…
Read MoreRandomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma
International Journal of Surgical Protocols 2023 September 26 [Link] Paul H Sugarbaker Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare disease that progresses within the peritoneal cavity and only disseminates to systemic sites in the terminal months of the disease. For this malignancy, there are several regimens of chemotherapy that have been accepted as…
Read MoreImpact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC
Annals of Surgical Oncology 2023 January [Link] Ambarish Chatterjee, Shigeki Kusamura, Dario Baratti, Marcello Guaglio, Luigi Battaglia, Marcello Deraco Abstract Background: The available data on the role of perioperative systemic chemotherapy (SC) for diffuse malignant peritoneal mesothelioma (DMPM) patients undergoing (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is heterogeneous and unstandardized. This study aimed to evaluate…
Read MoreThe role of single nucleotide polymorphisms related to iron homeostasis in mesothelioma susceptibility after asbestos exposure: a genetic study on autoptic samples
Frontiers in Public Health 2023 October 24 [Link] Pierangela Grignani, Silvia Damiana Visonà, Maria Vittoria Fronda, Paola Borrelli, Maria Cristina Monti, Barbara Bertoglio, Adelaide Conti, Paolo Fattorini, Carlo Previderè Abstract Asbestos-related diseases still represent a major public health problem all over the world. Among them, malignant mesothelioma (MM) is a poor-prognosis cancer, arising from the…
Read MoreContribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology
European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…
Read MoreBrain Metastases With Malignant Peritoneal Mesothelioma: Never Reported Before
Cureus 2023 August 19 [Link] Darshan Lal, Merissa Misiura, Waqas Adeel, Rizwan Tariq Abstract Malignant mesothelioma is a very rare diagnosis. Malignant mesotheliomas arise from surface linings of pleura, peritoneal cavity, or tunica vaginalis and pericardium with pleural malignant mesotheliomas being the most common. The incidence of brain metastases has been very low with malignant…
Read MoreZimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
World Journal of Clinical Cases 2023 August 6 [Link] Xiao-Dong Peng, Zhen-Yu You, Lian-Xiang He, Qi Deng Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare cancer with a poor prognosis at advanced stage, and the standard first-line treatment for inoperable patients is chemotherapy. Although combining programmed cell death 1 (PD-1) inhibitors with chemotherapy is…
Read More2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma
Annals of Surgical Oncology 2023 July 23 [Link] Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Shigeki Kusamura, Marcello Deraco Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive primary peritoneal disease, with recommended treatment, in eligible patients, of a combination of complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). As…
Read MoreCisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform
Scientific Reports 2023 July 19 [Link] Steven D Forsythe, Richard A Erali, Nicholas Edenhoffer, William Meeker, Nadeem Wajih, Cecilia R Schaaf, Preston Laney, Cristian D Vanezuela, Wencheng Li, Edward A Levine, Shay Soker, Konstantinos I Votanopoulos Abstract Peritoneal mesothelioma (PM) is a rare malignancy with poor prognosis, representing about 10-15% of all mesothelioma cases. Herein…
Read MoreMolecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies
ESMO Open 2023 July 13 [Link] M V Dietz, J P van Kooten, M S Paats, J G V J Aerts, C Verhoef, E V E Madsen, H J Dubbink, J H von der Thüsen Abstract Background: Peritoneal mesothelioma (PeM) is a rare malignancy with a poor prognosis. Currently there is a lack of effective…
Read More